Orphan Incentives: Voucher Price Drop Gives Some Sponsors 'Pause'

Is the lower sale price making the opportunity for a priority review voucher less an incentive for orphan development?

Priority Review Voucher

The incentive spurred by the US FDA's rare pediatric disease priority review voucher (PRV) may be eroding as its value has dropped, potentially forcing a rethink of financing models in the space.

A voucher sale can create needed dollars for a small company to sustain itself for future drug development in the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Rare Diseases

More from Pink Sheet